Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Study: Aromatase inhibitors should be first-line treatment
December 30th, 2004
Women with the type of breast cancer normally treated with tamoxifen could instead benefit from a class of drugs called aromatase inhibitors, concluded authors of a fast-track study published online on December 8, 2004, in The Lancet. Tamoxifen therapy for 5 years after surgery is the established treatment for postmenopausal women with hormone-sensitive breast cancer. However, its use is associated with several side effects, including endometrial cancer and blood-clotting disorders. The ATAC study is an international collaboration that compared the safety and efficacy of tamoxifen with anastrozole alone and the combination of both drugs for 5...
Source: Women's Health Weekly (2004-12-30)
|
